Table 1 Baseline characteristics of patients
LEN monotherapy (n = 39) | LEN combination (n = 72) | LEN + PD1 (n = 30) | LEN + HAIF/TACE (n = 24) | LEN + PD1 + HAIF/TACE (n = 16) | |
|---|---|---|---|---|---|
Age (Median ± SE) | 50 ± 13.3 | 51 ± 11.9 | 50.5 ± 10.6 | 55 ± 13.1 | 50 ± 12.8 |
Gender (Male/Female) | 37/2 | 66/6 | 28/2 | 23/1 | 13/3 |
BCLC stage (A/B/C) | 6/11/22 | 11/14/47 | 5/5/20 | 3/5/16 | 3/3/10 |
HBV infection (Yes/No) | 33/6 | 65/7 | 28/2 | 22/2 | 13/3 |
AFP (ng/ml) (< 400/> 400) | 24/15 | 33/39 | 15/15 | 9/15 | 8/8 |
Median follow-up (week) | 44.7 | 45.1 | 48.9 | 45.2 | 36.4 |
Child-Pugh (A/B) | 7/32 | 7/65 | 4/26 | 2/24 | 16/16 |